A patient with childhood-onset steroid-resistant nephrotic syndrome (SRNS) carried two missense variants in MYO1E—A92E and G562R—arranged in trans, investigators reported. Both substitutions map outside the canonical P-loop and switch subdomains of the Myo1e motor domain. The residues are highly conserved and, according to sequence-based structural prediction, sit within predicted α-helices. The altered side chains are larger and charged compared with the native residues; authors noted this property could reduce protein stability or interfere with normal folding. The report did not provide broader genetic cohort data, clinical follow-up beyond the index case, or epidemiological frequencies for these variants.
The study team examined localization in podocyte-derived cells. Wild-type Myo1e localized to intercellular junctions and colocalized with filamentous actin. By contrast, both A92E and G562R mutants failed to localize to junctional sites and showed reduced overlap with actin structures. The cellular phenotype was consistent across the reported imaging experiments, indicating a loss of normal membrane–actin association for the mutant proteins. Investigators interpreted these results as evidence that substitutions outside major motor motifs can nonetheless perturb subcellular targeting in a cell type directly relevant to glomerular filtration.
The G562R substitution produced an additional, distinct cellular signature: formation of cytoplasmic aggregates. The authors observed that aggregate prevalence was partially dependent on expression level, implying a dose-related propensity for misfolding or condensation. Fluorescence recovery after photobleaching (FRAP) experiments demonstrated decreased recovery for G562R compared with wild-type, a result the study team reported as impaired protein dynamics. The combination of aggregation and slowed exchange suggests that G562R disrupts not only steady-state localization but also the mobility and turnover of Myo1e in cells.
Biochemical assays yielded variant-specific functional outcomes. In vitro ATPase measurements indicated a marked loss of ATPase activity for the G562R mutant relative to wild-type protein, according to the authors. The A92E mutant retained ATPase activity similar to wild-type, however, it showed reduced in vitro motility when tested in the reported motility assays and exhibited decreased thermal stability. Those data argue for distinct mechanistic defects: G562R primarily compromises enzymatic activity and protein dynamics, while A92E impairs mechanical output and stability despite preserving ATPase catalysis.
Together, the cellular localization defects, altered actin association, aggregation behavior, and variant-specific biochemical impairments formed the basis for the authors’ conclusion that A92E and G562R compromise Myo1e function in ways consistent with a pathogenic role in SRNS. The paper connects molecular dysfunction to a disease-relevant cell type—podocytes—strengthening mechanistic plausibility.
At the same time, the article is a preprint and has not been certified by peer review, a fact the authors disclosed. The source did not report in vivo functional data or rescue experiments in animal models, nor did it present population-level allele frequencies or segregation analysis beyond the single patient case. Specific experimental parameters—such as expression levels used for cellular imaging, exact motility assay conditions, or sample sizes for each assay—were not detailed in the abstract; the full text and supplementary material would need to be consulted for those methodological specifics. The report therefore establishes compelling functional evidence in cells and purified protein but leaves open key translational questions: whether these variants segregate with disease in families, how they affect glomerular physiology in vivo, and whether targeted interventions could restore Myo1e localization or function.
Investigators and clinicians reading this preprint should treat the findings as mechanistic and hypothesis-generating. Peer review, replication, and additional genetic or in vivo validation will be required to confirm causality and to guide potential clinical interpretation or genetic counseling for patients with similar MYO1E variants.